UCB - Latest News and Information
Technology Pulse
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
UCB
UCB is a global biopharmaceutical leader focused on creating valuable solutions that improve the lives of people living with neurological and autoimmune conditions. The company operates worldwide with a focus on research, development, and patient support in areas such as epilepsy, Parkinson’s-related disorders, and autoimmune diseases. Based in Belgium, UCB emphasizes innovative science and patient-centric programs through its UCBCares initiative and ongoing clinical studies and publications.
Vimseltinib
Havas Red Appoints Erin Sing to Executive Director, Melbourne Role
CMS's Medicare Price Negotiations Start Round Three
Leqembi Starts to Deliver for Eisai and Biogen
Miles Gerson, Sofia Guerra Among VCs Landing New Roles
Bimekizumab Demonstrates Superiority Over Risankizumab in Psoriatic Arthritis Trial
‘Over and Above’ Responses Seen with Envudeucitinib for Plaque Psoriasis
Zelestra Brings Spanish 162MW Solar PV Portfolio Online
UCB Bags First EU Approval for Rare Genetic Disease TK2d
2025 Novel Small Molecule FDA Drug Approvals
No recent deals for this company.
